PODD vs GKOS vs BIO
161 measures in 16 categories, one definition each, computed from filings and market data.
BIO54.6
Bio-Rad Laboratories, Inc.
Healthcare · Medical - Devices
$353.70 −3.05%$9.5B mkt cap
Score DNA
Price, rebased to 100 three years ago
PODD GKOS BIO · weekly adjusted closesSmart money 8Valuation 16Profitability (TTM) 12Returns on capital 11Growth 17Margin history & stability 7Liquidity (latest quarter) 7Leverage & solvency (latest quarter) 13Efficiency 11Cash flow & earnings quality 7Dividends & buybacks 9Scores & forensic checks 15Per share 7Size (TTM) 8Price performance 9Technicals 4
● marks the highest or lowest value where that direction is plainly stronger (margins, returns, coverage, leverage); multiples and yields are left unmarked. Bars show each stock's percentile within its own industry. n/a: the measure does not apply to lenders and insurers.
Smart money
8 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| Insider open-market buys, 180d | 2 | 0 | 0 |
| Insider $ bought, 180d | $0.56M | — | — |
| Congress purchases, 180d | 3 | 0 | 0 |
| Last Congress purchase | 2026-09-11 | — | — |
| 13F net change in holders | −56 | +32 | — |
| ETFs adding shares, 30d | 548 | 283 | 264 |
| ETFs trimming, 30d | 470 | 216 | 172 |
| Net ETF funds, 30d | +78 | +67 | +92 |
Valuation
16 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| P/E (TTM) | 26.1x
52nd
|
— | 42.5x
78th
|
| PEG (P/E ÷ 3-yr EPS CAGR) | 0.32
13th
|
— | — |
| Price / sales | 3.2x
47th
|
15.9x
93rd
|
3.7x
57th
|
| Price / book | 6.9x
75th
|
14.2x
93rd
|
1.3x
11th
|
| Price / tangible book | 8.4x
59th
|
16.7x
88th
|
1.2x
2nd
|
| Price / free cash flow | 32.8x
67th
|
— | 26.8x
50th
|
| Price / operating cash flow | 19.1x
44th
|
— | 19.2x
47th
|
| Enterprise value | $10.2B
83rd
|
$9.5B
77th
|
$9.0B
72nd
|
| EV / sales | 3.3x
47th
|
15.6x
93rd
|
3.5x
50th
|
| EV / EBITDA | 15.4x
45th
|
— | 8.9x
8th
|
| EV / EBIT | 18.3x
30th
|
— | 10.4x
6th
|
| EV / free cash flow | 34.2x
58th
|
— | 25.6x
42nd
|
| Earnings yield | 3.8%
77th
|
-1.9%
40th
|
2.4%
65th
|
| FCF yield | 3.0%
60th
|
-0.1%
38th
|
3.7%
70th
|
| Operating cash flow yield | 5.2%
68th
|
-0.0%
27th
|
5.2%
67th
|
| Graham number (per share) | $49.93
59th
|
— | $223.45
96th
|
Profitability (TTM)
12 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| Gross margin | 71.1%
72nd
|
79.1%
88th
|
51.9%
23rd
|
| EBITDA margin | 21.7%
78th
|
-22.3%
20th
|
39.4%
98th
|
| Operating margin | 16.9%
82nd
|
-13.1%
27th
|
9.1%
58th
|
| EBIT margin | 18.3%
83rd
|
-29.8%
20th
|
33.7%
97th
|
| Net margin | 12.3%
82nd
|
-30.7%
22nd
|
8.6%
67th
|
| NOPAT margin | 12.8%
77th
|
-10.4%
27th
|
5.8%
55th
|
| FCF margin | 9.8%
63rd
|
-2.0%
35th
|
13.6%
73rd
|
| Operating cash flow margin | 16.7%
65th
|
-0.2%
27th
|
19.0%
75th
|
| R&D / revenue | 11.3%
63rd
|
28.9%
86th
|
10.1%
47th
|
| SG&A / revenue | 42.9%
43rd
|
63.1%
72nd
|
32.7%
20th
|
| Stock comp / revenue | 2.6%
43rd
|
13.1%
80th
|
0.6%
7th
|
| Effective tax rate | 24.1%
83rd
|
21.0%
21st
|
36.5%
97th
|
Returns on capital
11 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| ROE (on average equity) | 26.0%
95th
|
-26.0%
29th
|
3.1%
56th
|
| ROA | 11.3%
93rd
|
-19.7%
18th
|
2.2%
58th
|
| ROIC | 21.3%
93rd
|
-12.7%
27th
|
2.2%
51st
|
| ROCE | 23.1%
95th
|
-22.3%
18th
|
9.4%
73rd
|
| Return on tangible assets | 16.8%
97th
|
-19.2%
18th
|
8.5%
77th
|
| Cash ROIC (OCF / invested capital) | 27.8%
90th
|
-0.2%
25th
|
7.3%
51st
|
| Gross profitability (GP / assets) | 68.6%
90th
|
52.7%
70th
|
13.1%
8th
|
| ROIC, 3-yr average | 15.5%
90th
|
-14.0%
29th
|
-3.5%
43rd
|
| ROIC, 5-yr average | 12.5%
80th
|
-16.1%
29th
|
-9.9%
33rd
|
| ROE, 5-yr average | 20.3%
88th
|
-19.9%
27th
|
-7.7%
40th
|
| Incremental ROIC | -41.6%
24th
|
-11.5%
37th
|
33.9%
55th
|
Growth
17 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| Revenue growth (TTM YoY) | 29.4%
86th
|
41.5%
93rd
|
1.4%
9th
|
| Revenue growth (QoQ) | 5.3%
35th
|
23.3%
92nd
|
9.9%
62nd
|
| Revenue CAGR, 3 yr | 27.7%
89th
|
27.3%
87th
|
-2.2%
2nd
|
| Revenue CAGR, 5 yr | 25.1%
83rd
|
16.6%
62nd
|
-2.1%
2nd
|
| Gross profit CAGR, 3 yr | 33.6%
90th
|
29.3%
88th
|
-3.5%
2nd
|
| Operating income CAGR, 3 yr | 82.3%
96th
|
— | -13.5%
8th
|
| Net income growth (TTM YoY) | 59.0%
79th
|
— | -30.3%
25th
|
| Net income CAGR, 3 yr | 81.4%
95th
|
— | — |
| EPS growth (TTM YoY) | 61.8%
75th
|
— | -29.2%
25th
|
| EPS CAGR, 3 yr | 82.0%
95th
|
— | — |
| EPS CAGR, 5 yr | — | — | -42.7%
0th
|
| FCF growth (TTM YoY) | -23.2%
17th
|
— | 1.6%
33rd
|
| FCF CAGR, 3 yr | — | — | 32.2%
50th
|
| Operating cash flow CAGR, 3 yr | 49.9%
74th
|
— | 18.3%
48th
|
| Book value CAGR, 3 yr | 37.4%
96th
|
4.9%
49th
|
-2.4%
33rd
|
| Dividend CAGR, 3 yr | — | — | — |
| Sustainable growth rate | 26.0%
89th
|
— | 2.4%
7th
|
Margin history & stability
7 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| Gross margin, 3-yr average | 70.3%
72nd
|
77.3%
87th
|
52.9%
23rd
|
| Operating margin, 3-yr average | 16.2%
85th
|
-25.1%
19th
|
10.4%
64th
|
| Net margin, 3-yr average | 14.5%
91st
|
-32.8%
19th
|
-10.2%
40th
|
| FCF margin, 3-yr average | 12.5%
77th
|
-10.7%
26th
|
11.4%
72nd
|
| Revenue stability (0-1) | 0.95
60th
|
0.75
25th
|
0.80
32nd
|
| Earnings stability (0-1) | 0.75
83rd
|
0.61
75th
|
0.11
23rd
|
| Margin stability (0-1) | 0.95
38th
|
0.98
83rd
|
0.97
64th
|
Liquidity (latest quarter)
7 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| Cash & short-term investments | $534.9M
77th
|
$286.2M
63rd
|
$1.6B
88th
|
| Net cash (− = net debt) | −$413.5M
32nd
|
$183.4M
80th
|
$414.8M
88th
|
| Working capital | $1.1B
80th
|
$413.4M
53rd
|
$2.1B
88th
|
| Current ratio | 2.48
37th
|
5.04
78th
|
3.14
45th
|
| Quick ratio | 1.83
40th
|
4.46
78th
|
2.33
48th
|
| Cash ratio (cash + ST investments / current liabilities) | 0.72
38th
|
2.80
68th
|
1.68
57th
|
| Defensive interval (days) | 248 days
30th
|
274 days
40th
|
678 days
88th
|
Leverage & solvency (latest quarter)
13 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| Total debt | $948.4M
70th
|
$102.8M
37th
|
$1.2B
75th
|
| Debt / equity | 0.67
60th
|
0.15
30th
|
0.17
32nd
|
| Net debt / equity | 0.29
53rd
|
−0.27
32nd
|
−0.06
44th
|
| Debt / assets | 30.0%
55th
|
11.2%
30th
|
11.7%
32nd
|
| Debt / capital | 40.0%
60th
|
13.1%
30th
|
14.4%
32nd
|
| Debt / EBITDA | 1.43
37th
|
— | 1.18
26th
|
| Net debt / EBITDA | 0.62
34th
|
— | −0.41
26th
|
| Interest coverage (EBIT / interest) | 8.8x
79th
|
−19.2x
13th
|
23.8x
88th
|
| Cash interest coverage | 8.1x
75th
|
−0.1x
25th
|
13.4x
87th
|
| Debt payback (years of OCF) | 1.9 yrs
28th
|
— | 2.4 yrs
35th
|
| Liabilities / assets | 55.1%
63rd
|
25.9%
20th
|
30.0%
28th
|
| IS credit model rating | AA | BBB+ | AA |
| Implied credit spread (bps) | 80
17th
|
225
40th
|
80
17th
|
Efficiency
11 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| Asset turnover | 0.92
82nd
|
0.64
53rd
|
0.25
3rd
|
| Fixed asset turnover | 3.56
21st
|
3.37
19th
|
3.85
31st
|
| Inventory turnover | 1.9
60th
|
2.1
66th
|
1.6
31st
|
| Receivables turnover | 5.9
38th
|
5.5
28th
|
5.7
33rd
|
| Days sales outstanding | 62 days
62nd
|
66 days
72nd
|
64 days
65th
|
| Days inventory outstanding | 193 days
40th
|
177 days
34th
|
231 days
67th
|
| Days payables outstanding | 45 days
37th
|
47 days
38th
|
41 days
27th
|
| Cash conversion cycle (days) | 209 days
47th
|
196 days
43rd
|
254 days
77th
|
| Capex / revenue | 7.0%
91st
|
1.8%
19th
|
5.4%
79th
|
| Capex / depreciation | 2.02
90th
|
0.25
12th
|
0.95
60th
|
| Operating expense ratio | 54.0%
37th
|
91.0%
81st
|
42.0%
12th
|
Cash flow & earnings quality
7 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| Operating cash flow / net income | 1.36
37th
|
— | 2.21
85th
|
| FCF / net income | 0.79
15th
|
— | 1.59
70th
|
| FCF / operating cash flow | 58.4%
40th
|
— | 71.7%
55th
|
| Capex / operating cash flow | 41.6%
60th
|
— | 28.3%
43rd
|
| Accruals ratio | -4.1%
65th
|
-19.6%
7th
|
-2.6%
73rd
|
| Sloan accruals ratio | -7.5%
27th
|
1.1%
62nd
|
-3.4%
40th
|
| Earnings quality score (0-1) | 1.00
48th
|
— | 1.00
48th
|
Scores & forensic checks
15 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| IS score | 71
90th
|
39
45th
|
55
65th
|
| IS profitability | 71
93rd
|
20
28th
|
47
67th
|
| IS growth | 78
86th
|
52
32nd
|
21
2nd
|
| IS value | 43
63rd
|
27
7th
|
65
92nd
|
| IS momentum | 100
100th
|
50
14th
|
56
27th
|
| IS risk (safety) | 100
62nd
|
100
62nd
|
80
52nd
|
| IS quality | 86
93rd
|
43
33rd
|
78
75th
|
| IS balance sheet | 82
77th
|
41
33rd
|
93
95th
|
| IS earnings quality | 73
73rd
|
21
0th
|
78
90th
|
| IS cash flow | 47
60th
|
30
22nd
|
60
70th
|
| Piotroski F-score (0-9) | 9
95th
|
3
7th
|
7
70th
|
| Altman Z-score | 5.8
68th
|
19.7
93rd
|
3.4
55th
|
| Beneish M-score | −2.45
79th
|
−3.05
18th
|
−2.67
46th
|
| Ohlson O-score | −8.31
37th
|
−7.84
42nd
|
−9.41
15th
|
| IS credit score | 87
80th
|
64
55th
|
88
82nd
|
Size (TTM)
8 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| Market cap | $9.8B
80th
|
$9.7B
78th
|
$9.5B
75th
|
| Revenue | $3.1B
77th
|
$612.8M
42nd
|
$2.6B
73rd
|
| EBITDA | $663.6M
78th
|
−$136.9M
2nd
|
$1.0B
83rd
|
| Net income | $375.3M
82nd
|
−$188.0M
3rd
|
$222.4M
78th
|
| Free cash flow | $298.3M
78th
|
−$12.2M
28th
|
$353.1M
80th
|
| Total assets | $3.2B
67th
|
$920.5M
47th
|
$10.3B
85th
|
| Shareholders' equity | $1.4B
68th
|
$682.5M
57th
|
$7.2B
87th
|
| Employees | 5,400
70th
|
1,094
43rd
|
7,450
73rd
|
Price performance
9 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| 1 day | +1.7% | −0.5% | −3.0% |
| 1 week | +4.3% | −0.5% | −3.4% |
| 1 month | −0.3% | +2.1% | −7.5% |
| 3 months | −15.7% | +6.0% | +17.2% |
| 6 months | −30.7% | +32.1% | +18.3% |
| Year to date | −50.1% | +48.9% | +15.9% |
| 1 year | −54.8% | +92.6% | +15.6% |
| 3 years, cumulative | +5.7% | +132.1% | −0.9% |
| 5 years, cumulative | −51.5% | +265.0% | −51.0% |
Technicals
4 measures| Measure | PODD | GKOS | BIO |
|---|---|---|---|
| RSI 14 | 55.6 | 48.8 | 39.5 |
| From 52-week high | −60.2% | −14.0% | −10.7% |
| From 52-week low | +11.6% | +125.3% | +49.4% |
| Beta | 1.10 | 0.69 | 1.07 |
InsiderStreet reports findings from filings and market data. A comparison is not a recommendation to buy or sell either stock.Every figure is computed in code · data as of 2026-10-17